AUA 2018: Brain Metastasis from Renal Cell Carcinoma: An Institutional Study

San Francisco, CA (UroToday.com) Metastatic spread in renal cell carcinoma (RCC) often goes to the lungs and bones, and less commonly to the liver and brain. Prior studies1 have examined the spread of RCC utilizing population based analyses, and identified predictors of metastatic spread based on clinical features and histology. In this abstract, the authors use their institutional data to specifically focus on RCC related brain metastases, a relatively rare presentation. 

AUA 2018: Use of Surveillance vs Active Treatment for Renal Masses ≤7 Cm: Results from the MUSIC KIDNEY Regional Collaborative

San Francisco, CA (UroToday.com) Active surveillance has now become an established first-line therapeutic option for cT1a renal masses. However, uptake of active surveillance (AS) has not been universal. Quality control measures have been instituted internationally to help further evaluate its utilization and efficacy.

AUA 2018: Frozen Sections for Margins During Partial Nephrectomy Do Not Influence Recurrence Rates

San Francisco, CA (UroToday.com) Frozen sections, or intra-operative pathologic evaluations, are often sent during various oncologic operations to help assist in the decision for further intraoperative management. In cystectomies, frozen sections are often sent from the distal ureters and urethra; in prostatectomy, frozen sections are sometimes sent from concerning lymph nodes; in penectomies/partial penectomies, proximal margins are sent to confirm adequate distance from disease; in partial nephrectomy for renal cell carcinoma (RCC), frozen sections are sometimes sent from the base of the resection bed to confirm complete excision.

AUA 2018: Mini-Subcostal Incision for Open Radical Nephrectomy in the Minimally Invasive Era

San Francisco, CA (UroToday.com) As robotic partial nephrectomy continues to gain traction, there is increasing utilization of minimally invasive approaches to radical nephrectomy. While most institutions are comfortable with pure laparoscopic radical nephrectomy, some institutions have even begun to move to robotic radical nephrectomy. However, health care costs become a major obstacle to these novel techniques – is it cost effective to do a robotic nephrectomy when a laparoscopic nephrectomy has similar outcomes?

AUA 2018: “Pin the Tumor on the Kidney”: An Evaluation of How Surgeons Translate CT and MRI data to 3D Models

San Francisco, CA USA (UroToday.com) Ms Wake from New York University School of Medicine presents here research on patient-specific 3D models as tools for pre-operative surgical planning, virtual reality (VR) simulators, intra-operative guidance and patient education. These 3D models provide an intuitive understanding of the surgical anatomy, however there is limited data to quantify the added value of these models. Her research team sought out to identify the ability of surgeons to translate their CT or MRI understanding to a 3D model.

AUA 2018: Is There a Role for Nephron Sparing Cytoreductive Partial Nephrectomy in Metastatic Renal Cell Carcinoma?

San Francisco, CA (UroToday.com) Cytoreductive nephrectomy, or removal of the primary tumor, is a mainstay of therapy for patients with metastatic renal cell carcinoma (mRCC). However, in the era of targeted therapy, even the role of cytoreductive nephrectomy has been called into question – to the point that many clinicians generally justify a cytoreductive nephrectomy in patients whom the volume of disease in the kidney predominates the total volume of disease. In patients with a significant metastatic disease but a small primary, the role for cytoreductive nephrectomy is being questioned.

AUA 2018: Predicting Chemo Sensitivity in Urothelial Malignancy: Nanotech and Precision Medicine

San Francisco, CA (UroToday.com) Chong-xian Pan, MD, a leading medical oncologist focused on bladder cancer, gave a State of the Art Lecture on his work. He focused on two areas: microdosing approach to identify chemoresistance prior to chemotherapy and cancer-specific nanoparticles to improve chemotherapy, photodynamic therapy, and immunotherapy.